NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies will be using its technologies to support Bristol-Myers Squibb's drug discovery programs.
Under a deal announced today, Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work. The research, Kinaxo said, will allow Bristol-Myers Squibb to make more informed decisions at different stages of the drug discovery process, such as selecting the best compounds for clinical development.
Terms of the deal were not disclosed.
In a statement, Jutta Fritz, head of business development for Kinaxo said the agreement is a "major milestone" as the company expands its business into the US.